Corcept Therapeutics | CORT - Operating Profit


Corcept Therapeutics reported $4.49M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Ardelyx USD 4.67M 19.07M Sep/2025
Assertio Holdings USD -3.05M 569K Sep/2024
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
J&J USD 5.59B 1.81B Dec/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Lexicon Pharmaceuticals USD -55.35M 10.02M Jun/2024
Merck USD 6.24B 318M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 13.15M 2.92M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025